Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Adds Single-Shot AF-Ablation Balloon With Apama Acquisition

Executive Summary

Boston Scientific will pay about $300m for the Campbell, California-based maker of the Apama radiofrequency balloon catheter system for the treatment of atrial fibrillation. Boston Scientific plans to integrate Apama's technology with its Rhythmia HDx mapping system.

You may also be interested in...



Boston Scientific Gulps Down Claret After Cryterion, In Double-Whammy July

Boston Scientific has inked a deal of up to $270m for embolic protection system developer Claret Medical, marking its second acquisition in the space of two weeks.

Global Approvals Analysis: Emerging Markets Drive Volume Of OUS Approvals

The numbers of medical device approvals were up in most regions outside the US and the biggest surge, by percentage, was in approvals from emerging markets and the so-called BRIC countries. It remains to be seen if the trend will continue in 2018, but many companies are already counting on important non-US approvals coming in the next year.

Start-Up Spotlight: Apama Medical, Targeting AFib With An RF-Balloon Combo

Founded and led by serial entrepreneur Amr Salahieh, Apama Medical is developing a system that aims to combine the advantages of two approaches for treating atrial fibrillation: point-by-point radiofrequency-based ablation and cryoballoon ablation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT121581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel